Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences plans to introduce the Cologuard Plus™ test in 2025, building on a decade of patient impact.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
At Exact Sciences, we’re pioneering a paradigm shift in cancer detection. The Cancerguard™ test in development is being designed to detect multiple cancers in their earliest stages from a single blood draw.1 So we can start to close the gaps that exist in today’s cancer screening.
Because if we can detect cancer early, we may be able to stay one step ahead of it.2,3
See our latest presented data on the evolution of a multi-biomarker class approach to multi-cancer early detection testing
There is a moment when we all have the upper hand against cancer. It’s before the first signs and symptoms show up, when more options are on the table. But too often, early detection opportunities are unavailable or missed.1 Today, we only have routine screening tests for about one-third of diagnosed cancers.2* This means that many cancers go undetected until it’s too late.1
Our vision for the Cancerguard™ test aims to transform cancer screening.
*Calculated using estimated new diagnoses and deaths from cancers that have standard-of-care screening: breast, cervical, colorectal, and lung (high risk) against all sites.
The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.
References